LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Search

Bio-Techne Corp

Closed

SectorHealthcare

61.68 -2.87

Overview

Share price change

24h

Current

Min

61.07

Max

63.48

Key metrics

By Trading Economics

Income

56M

38M

Sales

-30M

287M

P/E

Sector Avg

130.122

80.03

EPS

0.53

Dividend yield

0.5

Profit margin

13.326

Employees

3,100

EBITDA

71M

78M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+4.99% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.50%

2.29%

Market Stats

By TradingEconomics

Market Cap

397M

9.9B

Previous open

64.55

Previous close

61.68

News Sentiment

By Acuity

34%

66%

109 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Bio-Techne Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 lis 2025, 22:36 UTC

Earnings

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Peer Comparison

Price change

Bio-Techne Corp Forecast

Price Target

By TipRanks

4.99% upside

12 Months Forecast

Average 66.71 USD  4.99%

High 70 USD

Low 60 USD

Based on 9 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

49.67 / 50.24Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

109 / 374 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat